Inanovate Spotlight

Inanovate completes testing and benchmarking of Bio-ID. Bio-ID Technology Review

The Bio-ID lowers the cost and improves the accuracy of diagnostic tests by rapidly and precisely measuring the concentration of multiple disease related biological molecules (biomarkers) from patient blood samples.

The Bio-ID consists of a compact bench-top analyzer and disposable test cartridges. The end-user simply loads test samples into a Bio-ID cartridge, inserts the cartridge into the analyzer, hits the ‘go’ button and walks away.”

InanovateBreast Cancer Monitoring Test

Inanovate is now advancing the first application of the Bio-ID: A low-cost blood test that can detect breast cancer recurrent at a stage when it may still be curable.

The test combines the Bio-ID platform with 7 patent protected breast cancer specific biomarkers.”

In a 400 patient trial with our clinical partners Sanford Health, the biomarkers demonstrated the capability to identify breast cancer to a Sensitivity of 83% at a Specificity of 70%.

This means that over 8 out of every 10 cases of cancer were correctly identified. If confirmed through our extended trials, such a test will have a significant impact on clinical practice, saving tens of thousands of lives each year, and improving the quality of life for millions more. For more information click here..

InanovateInanovate’s Mission

“To provide the Life Sciences industry with the world’s leading technology for screening and analysing proteins.”

To achieve this mission, Inanovate has developed a revolutionary technology for the detection and measurement of multiple proteins called Longitudinal Assay Screening (LAS). First developed in 2010, LAS has since been integrated into Inanovate’s first product – The Bio-ID.

The Bio-ID is a new category of protein screening technology that can play a key role in the development and implementation of next generation of diagnostics and therapeutics.

InanovateOur History

In 2010 Inanovate begun the development of a novel approach to the detection and measurement of multiple proteins called Longitudinal Assay Screening (LAS). LAS was developed to help users in both research and clinical markets to accurately detect and measure multiple proteins from patient samples at virtually any concentration, without the need for multiple sample dilutions or complex preparations. Recently, Inanovate successfully completed testing and benchmarking the first platform to integrate LAS: The Bio-ID.

Read More